Legal & General Group
CDAK

Legal & General Group’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Legal & General Group’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,661
Closed -$10K – 3733
2022
Q1 		$10K Hold
1,661
– – ﹤0.01% 3414
2021
Q4 		$19K Hold
1,661
– – ﹤0.01% 3300
2021
Q3 		$27K Hold
1,661
– – ﹤0.01% 3173
2021
Q2 		$31K Buy
1,661
+1,118
+206% +$21.5K ﹤0.01% 3125
2021
Q1 		$8K Hold
543
– – ﹤0.01% 3439
2020
Q4 		$18K Buy
+543
New +$7.18K ﹤0.01% 3148

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Legal & General Group's CDAK Position: Q2 2022 in Review

Legal & General Group sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 1,661 shares — an estimated $10K sold.

Legal & General Group first reported a position in CDAK in Q4 2020 and held it in 6 quarters. The position peaked at $31K in Q2 2021. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

  • Legal & General Group reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 1,661 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $10K.
  • Legal & General Group first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
  • Legal & General Group's Codiak BioSciences, Inc. Common Stock position peaked at $31K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.